As of Jul 31
| -0.19 / -1.07%|
The 8 analysts offering 12-month price forecasts for Aratana Therapeutics Inc have a median target of 26.00, with a high estimate of 38.00 and a low estimate of 23.00. The median estimate represents a +47.56% increase from the last price of 17.62.
The current consensus among 9 polled investment analysts is to Buy stock in Aratana Therapeutics Inc. This rating has held steady since July, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.